SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : JMED - Jones Pharma (specialty pharmaceutical mfr) -- Ignore unavailable to you. Want to Upgrade?

To: Michael Burry who wrote (204)2/26/1999 12:05:00 PM
From: Mikeh  Read Replies (2) | Respond to of 268
 
Its good to see a few posts on this thread. The stock has drifted in the mid20s to high 30s for the last two years. So it can be frustrating to those that bought in the upper 30s. This one requires some patience, but I don't worry about it. The right drug acquisition, however long in coming, will boost the stock price. Meanwhile, I collect the dividend and buy on the bigger dips. So far that has worked for me.

With all the large merger activity of the last two years, you have to think there are good acquisition targets out there.



To: Michael Burry who wrote (204)4/6/1999 5:37:00 PM
From: babette spatz  Read Replies (1) | Respond to of 268
 
Hello Michael!!

Since you seem to be the only font of information and/or knowledge about JMED. Any news? Any buying of companies and or drugs in the offing? Is Mr. Jones still away on vacation? Please let him know that those who but stocks for POSITIVE results need a reason to stay invested. The past performance, certainally about a year or two, has only negative results i. e. LOOSING $$$$$


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News